Total Payments
$54,275
2023 Payments
$397.68
Companies
3
Transactions
53
Payment Breakdown by Category
Research$50,740 (93.5%)
Travel$2,610 (4.8%)
Food & Beverage$905.76 (1.7%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $50,740 | 14 | 93.5% |
| Travel and Lodging | $2,610 | 13 | 4.8% |
| Food and Beverage | $905.76 | 25 | 1.7% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$50,740
14 transactions
General
$3,535
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $52,876 | 44 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $1,379 | 8 | $0 (2020) |
| PFIZER INC. | $20.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $397.68 | 3 | Eli Lilly and Company ($397.68) |
| 2022 | $19,907 | 7 | Eli Lilly and Company ($19,907) |
| 2021 | $268.77 | 2 | Eli Lilly and Company ($248.77) |
| 2020 | $31,258 | 10 | Eli Lilly and Company ($29,879) |
| 2019 | $1,278 | 25 | Eli Lilly and Company ($1,278) |
| 2018 | $1,166 | 6 | Eli Lilly and Company ($1,166) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $150.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $142.50 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $105.18 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 08/15/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $16,605.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 08/15/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $308.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,214.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $298.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 03/07/2022 | Eli Lilly and Company | — | — | In-kind items and services | $897.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 06/03/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 03/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $248.77 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 07/20/2020 | Eli Lilly and Company | — | — | In-kind items and services | $205.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/06/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $29,674.16 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Travel and Lodging | In-kind items and services | $69.66 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $49.60 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $49.58 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $34.71 | General |
| Category: VACCINE | ||||||
| 01/28/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Travel and Lodging | In-kind items and services | $892.04 | General |
| Category: VACCINE | ||||||
| 01/28/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Travel and Lodging | In-kind items and services | $159.11 | General |
| Category: VACCINE | ||||||
| 01/28/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $84.31 | General |
| Category: VACCINE | ||||||
| 01/28/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Travel and Lodging | Cash or cash equivalent | $39.80 | General |
| Category: VACCINE | ||||||
| 12/19/2019 | Eli Lilly and Company | — | — | In-kind items and services | $307.13 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 12/02/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $40.60 | General |
| 12/02/2019 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $12.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $30,779 | 5 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $16,905 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $1,214 | 1 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $897.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $546.77 | 2 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $150.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $142.50 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $105.18 | 1 |
About Dr. Toby Briskin, M.D
Dr. Toby Briskin, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Bedford, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245345172.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Toby Briskin, M.D has received a total of $54,275 in payments from pharmaceutical and medical device companies, with $397.68 received in 2023. These payments were reported across 53 transactions from 3 companies. The most common payment nature is "" ($50,740).
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Bedford, OH
- Active Since 08/20/2006
- Last Updated 06/20/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1245345172
Products in Payments
- GARDASIL 9 (Biological) $1,379
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Bedford
Madhuri Devdhar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $32,561
Endocrinology, Diabetes & Metabolism $32,561
Vani Kotha, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $23,355
Endocrinology, Diabetes & Metabolism $23,355
Dr. Nneka Iroka-Onwusoba, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $134.98
Endocrinology, Diabetes & Metabolism $134.98